Research analysts at HC Wainwright started coverage on shares of uniQure (NASDAQ:QURE) in a research report issued to clients and investors on Friday. The firm set a “buy” rating and a $28.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 84.94% from the stock’s previous close.
Other analysts have also recently issued research reports about the company. Zacks Investment Research raised uniQure from a “sell” rating to a “hold” rating and set a $21.00 price target on the stock in a report on Tuesday, October 24th. Leerink Swann boosted their target price on uniQure from $19.00 to $26.00 in a report on Tuesday, November 7th. Oppenheimer reiterated a “hold” rating on shares of uniQure in a research report on Friday, November 24th. Finally, Evercore ISI initiated coverage on uniQure in a report on Tuesday, November 7th. They set an “outperform” rating and a $22.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. uniQure currently has an average rating of “Buy” and an average price target of $18.75.
Shares of uniQure (NASDAQ:QURE) opened at $15.14 on Friday. The company has a quick ratio of 3.64, a current ratio of 3.64 and a debt-to-equity ratio of 0.73. uniQure has a fifty-two week low of $4.72 and a fifty-two week high of $21.35.
TRADEMARK VIOLATION NOTICE: “uniQure (QURE) Coverage Initiated by Analysts at HC Wainwright” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/01/uniqure-qure-coverage-initiated-by-analysts-at-hc-wainwright.html.
uniQure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.